IRIDEX Corporation (IRIX), a developer of laser-based medical systems and consumable probes for treating glaucoma and retinal diseases, reported results for the third quarter ended October 3, 2026. This report matters because it tests a multi-year turnaround built on cost discipline and margin improvement. After generating positive adjusted EBITDA and positive operating cash flow in fiscal 2025, the company is pushing toward sustainable profitability. This quarter’s revenue miss and guidance reduction signal that demand headwinds in international markets are offsetting the operational progress management has made, making the path to profitability a central question for investors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Total revenue for the third quarter of 2026 was $10.2 million, down 19% from $12.5 million in the prior-year period and below the consensus estimate of roughly $12.6 million. GAAP net loss was $1.4 million, or $0.08 per share, compared with a net loss of $1.6 million, or $0.09 per share, a year earlier.
Within the mix, retina product revenue fell to $5.1 million from $6.7 million, driven primarily by weaker international demand. Revenue from the Cyclo G6 glaucoma product family was $3.2 million versus $3.5 million, as distributors worked through inventory purchased earlier in the year; approximately 11,900 Cyclo G6 probes were sold, down from 14,900 a year ago. The company sold 28 G6 glaucoma laser systems versus 30 in the prior-year quarter.
A bright spot was profitability. Gross margin rose to 42.4% from 32.1% a year earlier, helped by a one-time $0.8 million write-off recorded in the prior-year period, more favorable geographic mix, and sustained pricing discipline. Excluding that prior-year impact, pro forma gross margin was 38.7%, a 370 basis-point improvement. Non-GAAP adjusted EBITDA was a loss of $0.6 million, versus a $0.1 million loss a year ago.
On the balance sheet, cash and cash equivalents stood at $3.7 million as of October 3, 2026, down about $1.0 million from the prior quarter as the company invested in safety-stock inventory tied to its manufacturing relocation to San Jose.
IRIX shares dropped sharply following the November 17, 2026 release, with the stock falling by roughly 30% in after-hours trading. The reaction reflected two compounding concerns: a top-line miss and a meaningful reduction in full-year guidance. Management attributed the shortfall to softer-than-expected demand in Europe and Asia, distributor inventory digestion ahead of the headquarters relocation, and ongoing regulatory delays, particularly around PASCAL certification in Europe. While the gross-margin improvement was encouraging, investors appeared to weigh the revenue trajectory more heavily, given the company’s limited cash cushion and the recurring nature of its probe-based consumables business.
Management now expects full-year 2026 revenue of $46 million–$48 million, down from the prior range of $51 million–$53 million, with the guidance continuing to exclude revenue from the Middle East. The company maintained its outlook for adjusted operating expenses of $19 million–$19.5 million.
Looking ahead, management is positioning 2027 as a more profitable year. The completed manufacturing relocation to San Jose is expected to generate roughly $600,000 in annualized rent savings, and the company remains on track to transition major products to third-party contract manufacturers through 2027, a move intended to drive further gross-margin expansion.
Investors should monitor several factors. First, the pace at which safety-stock inventory converts back into revenue and cash, which management expects to support a return toward cash-flow breakeven. Second, the timing of regulatory clearances, including PASCAL MDR certification in Europe, which the company continues to expect in the first half of 2027. Third, whether deferred international orders, including Japan PASCAL shipments, materialize in the fourth quarter. Finally, watch the trajectory of the U.S. glaucoma business, which grew in the quarter and remains the company’s most stable growth engine. From what I see, these elements will be critical in determining whether the company can stabilize and move forward.
In my view, tools like Tickeron’s AI Screener can be helpful when evaluating companies in the medical technology space. I use it from time to time to filter for comparable names based on fundamentals, technical patterns, and sector trends, which adds context when reviewing earnings like these.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In 79 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for IRIX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of light-based medical systems and delivery devices
Industry MedicalNursingServices